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Corey CutlerIn this edition of BBMT, Platzbecker et al. [1]
reported the results of a comparative database review
comparing allogeneic stem cell transplants to DNA
hypomethylating therapy with azacytidine in patients
60 to 70 years of age. The authors perform a donor
vs no donor analysis comparing a cohort of patients
who underwent transplantation with a group who re-
ceived therapy with azacytidine after an unsuccessful
donor search or no search attempt (as a departmental
standard). In their analysis, an advantage for trans-
plantation becomes evident approximately 2 years
after transplantation, with a multivariate Cox regres-
sion analysis showing that transplantation was asso-
ciated with a significantly better overall survival
(hazard ratio 5 0.3, P 5 .007) at times greater
than 1 year from transplantation. Interestingly, there
did not appear to be a decrement in early survival in
the transplantation arm, possibly dispelling the myth
that early, upfront nonrelapse mortality is the price
to be paid for the chance at cure with allogeneic
transplantation.
As in all comparative database studies, there is in-
herent bias in this study, which the authors certainly
attempt to minimize. Favoring transplantation are
the biases that limit enrollment in the transplantation
arm to individuals eligible for, and who received, inter-
mediate to high-intensity transplantation conditioning
regimens, whereas patients with significant comorbid-
ity were excluded. Whether patients in the ‘‘no-
search’’ arm would have been eligible for intermediate
to high-intensity transplantation is unknown, although
this represents only a small group of individuals. In ad-
dition, nearly half of the transplantation arm received
induction chemotherapy before transplantation, which
biases the results toward a favorable transplantation
outcome, because only patients who survived induc-
tion, and perhaps even only those who had a favorableDana Farber Cancer Institute, Harvard Medical School,
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a result, the median blast count before transplantation
was stable when compared to the time of diagnosis in
the transplantation arm (11% vs 10%), whereas it
rose in the azacytidine cohort (12% vs 17%). Finally,
as in all comparative database studies, the size of the
original intended transplantation cohort can never be
determined, and no intention-to-treat analysis can be
performed. This sort of bias is unfortunately prevalent
among transplantation studies in myelodysplasia.
Other retrospective analyses have suggested transplan-
tation for patients with lower riskmyelodysplasia [2] or
early in the disease course [3] to improve outcome; un-
fortunately, patient selection in these analyses similarly
biases these conclusions.
Even in the absence of compelling prospective data
demonstrating a survival advantage for reduced inten-
sity transplantation in older individuals, it is clear that
this is becoming a more clinically accepted treatment
strategy, and that advanced age alone is not a contrain-
dication to transplantation [4,5]. In 2011, the Center
for International Blood and Marrow Transplant
Research registered 169 patients aged 65 years or
older to a prospective transplantation cohort study,
more than twice as many as in 2010, and more than
5 times the number of matched transplantations
registered at the Center for International Blood and
Marrow Transplant Research for individuals greater
than age 60 between the years 2002 and 2006
combined (W. Saber and M. Horowitz, personal
communication). Similar trends in Europe have also
been reported [6].
In an attempt to guide treatment decisions, a re-
cent Markov model has attempted to comparatively
analyze reduced intensity transplantation and
non-transplantation strategies in older patients with
myelodysplastic syndrome (MDS) [7]. This model
suggested an advantage to transplantation for individ-
uals with intermediate-2 and high-risk International
Prostate Symptom Score scores. However, Markov
models are just that – mathematical models – that
can guide therapy, but do not replace well-designed,
prospective comparative trials. There currently are
2 prospective trials that will address the role of re-
duced intensity allogeneic stem cell transplantation
in older individuals. The German multicenter trial
(NCT01404741, N. Kr€oger, PI) will treat 230 pa-
tients aged 55 to 70 with newly diagnosed MDS
Biol Blood Marrow Transplant 18:1318-1321, 2012 1321The Bottom Lineand secondary acute myelogenous leukemia with aza-
cytidine for 4 cycles, followed by biological assign-
ment to transplantation in the event of donor
availability, or continued azacytidine therapy in the
absence of a donor. Similarly, the Blood and Marrow
Transplant Clinical Trials Network is planning
a multicenter biological assignment study of almost
400 individuals aged 50 years or greater who will be
biologically assigned to reduced intensity transplanta-
tion or best supportive care, including hypomethylat-
ing therapy, at the time of transplantation referral
(Blood and Marrow Transplant Clinical Trials Net-
work 1102, R. Nakamura, C. Cutler, co-PIs). Al-
though slightly different in design, both of these
trials will be instrumental in solidifying the role of
transplantation in the therapy of MDS in older indi-
viduals. However, whether a true randomized trial
among patients with identified donors can ever be
performed is questionable.THE BOTTOM LINE
This study suggests that transplantation is associ-
ated with superior long-term outcomes in older pa-
tients with myelodysplastic disorder who have an
identified donor and who undergo transplantation in
comparison with azacytidine therapy. This study, al-
though imperfect, adds to the growing literature sup-
porting the role of allogeneic transplantation for
older individuals with MDS.ACKNOWLEDGMENTS
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